343 related articles for article (PubMed ID: 32804915)
1. TIGIT Can Exert Immunosuppressive Effects on CD8+ T Cells by the CD155/TIGIT Signaling Pathway for Hepatocellular Carcinoma In Vitro.
Zhang C; Wang Y; Xun X; Wang S; Xiang X; Hu S; Cheng Q; Guo J; Li Z; Zhu J
J Immunother; 2020 Oct; 43(8):236-243. PubMed ID: 32804915
[TBL] [Abstract][Full Text] [Related]
2. CD155/TIGIT signaling regulates the effector function of tumor-infiltrating CD8+ T cell by NF-κB pathway in colorectal cancer.
Li S; Ding J; Wang Y; Wang X; Lv L
J Gastroenterol Hepatol; 2022 Jan; 37(1):154-163. PubMed ID: 34734434
[TBL] [Abstract][Full Text] [Related]
3. CD155T/TIGIT Signaling Regulates CD8
He W; Zhang H; Han F; Chen X; Lin R; Wang W; Qiu H; Zhuang Z; Liao Q; Zhang W; Cai Q; Cui Y; Jiang W; Wang H; Ke Z
Cancer Res; 2017 Nov; 77(22):6375-6388. PubMed ID: 28883004
[TBL] [Abstract][Full Text] [Related]
4. Blockade of TIGIT/CD155 Signaling Reverses T-cell Exhaustion and Enhances Antitumor Capability in Head and Neck Squamous Cell Carcinoma.
Wu L; Mao L; Liu JF; Chen L; Yu GT; Yang LL; Wu H; Bu LL; Kulkarni AB; Zhang WF; Sun ZJ
Cancer Immunol Res; 2019 Oct; 7(10):1700-1713. PubMed ID: 31387897
[TBL] [Abstract][Full Text] [Related]
5. Expression of TIGIT/CD155 and correlations with clinical pathological features in human hepatocellular carcinoma.
Duan X; Liu J; Cui J; Ma B; Zhou Q; Yang X; Lu Z; Du Y; Su C
Mol Med Rep; 2019 Oct; 20(4):3773-3781. PubMed ID: 31485637
[TBL] [Abstract][Full Text] [Related]
6. Blocking TIGIT/CD155 signalling reverses CD8
Liu L; Wang A; Liu X; Han S; Sun Y; Zhang J; Guo L; Zhang Y
J Transl Med; 2022 Jun; 20(1):280. PubMed ID: 35729552
[TBL] [Abstract][Full Text] [Related]
7. TIGIT and PD1 Co-blockade Restores ex vivo Functions of Human Tumor-Infiltrating CD8
Ge Z; Zhou G; Campos Carrascosa L; Gausvik E; Boor PPC; Noordam L; Doukas M; Polak WG; Terkivatan T; Pan Q; Takkenberg RB; Verheij J; Erdmann JI; IJzermans JNM; Peppelenbosch MP; Kraan J; Kwekkeboom J; Sprengers D
Cell Mol Gastroenterol Hepatol; 2021; 12(2):443-464. PubMed ID: 33781741
[TBL] [Abstract][Full Text] [Related]
8. The immune checkpoint TIGIT/CD155 promotes the exhaustion of CD8 + T cells in TNBC through glucose metabolic reprogramming mediated by PI3K/AKT/mTOR signaling.
Huang M; Yu X; Wang Q; Jiang Z; Li X; Chen W; Song C
Cell Commun Signal; 2024 Jan; 22(1):35. PubMed ID: 38216949
[TBL] [Abstract][Full Text] [Related]
9. Hepatocellular Carcinoma Cells Up-regulate PVRL1, Stabilizing PVR and Inhibiting the Cytotoxic T-Cell Response via TIGIT to Mediate Tumor Resistance to PD1 Inhibitors in Mice.
Chiu DK; Yuen VW; Cheu JW; Wei LL; Ting V; Fehlings M; Sumatoh H; Nardin A; Newell EW; Ng IO; Yau TC; Wong CM; Wong CC
Gastroenterology; 2020 Aug; 159(2):609-623. PubMed ID: 32275969
[TBL] [Abstract][Full Text] [Related]
10. T Cells Expressing Checkpoint Receptor TIGIT Are Enriched in Follicular Lymphoma Tumors and Characterized by Reversible Suppression of T-cell Receptor Signaling.
Josefsson SE; Huse K; Kolstad A; Beiske K; Pende D; Steen CB; Inderberg EM; Lingjærde OC; Østenstad B; Smeland EB; Levy R; Irish JM; Myklebust JH
Clin Cancer Res; 2018 Feb; 24(4):870-881. PubMed ID: 29217528
[No Abstract] [Full Text] [Related]
11. CD155/TIGIT, a novel immune checkpoint in human cancers (Review).
Liu L; You X; Han S; Sun Y; Zhang J; Zhang Y
Oncol Rep; 2021 Mar; 45(3):835-845. PubMed ID: 33469677
[TBL] [Abstract][Full Text] [Related]
12. Melanoma Cells Control Antimelanoma CTL Responses via Interaction between TIGIT and CD155 in the Effector Phase.
Inozume T; Yaguchi T; Furuta J; Harada K; Kawakami Y; Shimada S
J Invest Dermatol; 2016 Jan; 136(1):255-63. PubMed ID: 26763445
[TBL] [Abstract][Full Text] [Related]
13. TIGIT-Fc alleviates acute graft-versus-host disease by suppressing CTL activation via promoting the generation of immunoregulatory dendritic cells.
Zhang D; Hu W; Xie J; Zhang Y; Zhou B; Liu X; Zhang Y; Su Y; Jin B; Guo S; Zhuang R
Biochim Biophys Acta Mol Basis Dis; 2018 Sep; 1864(9 Pt B):3085-3098. PubMed ID: 29960041
[TBL] [Abstract][Full Text] [Related]
14. PD-1
Liu X; Li M; Wang X; Dang Z; Jiang Y; Wang X; Kong Y; Yang Z
Cancer Immunol Immunother; 2019 Dec; 68(12):2041-2054. PubMed ID: 31720814
[TBL] [Abstract][Full Text] [Related]
15. Immunoreceptor TIGIT inhibits the cytotoxicity of human cytokine-induced killer cells by interacting with CD155.
Zhang B; Zhao W; Li H; Chen Y; Tian H; Li L; Zhang L; Gao C; Zheng J
Cancer Immunol Immunother; 2016 Mar; 65(3):305-14. PubMed ID: 26842126
[TBL] [Abstract][Full Text] [Related]
16. Transcriptome Profiling Identifies TIGIT as a Marker of T-Cell Exhaustion in Liver Cancer.
Ostroumov D; Duong S; Wingerath J; Woller N; Manns MP; Timrott K; Kleine M; Ramackers W; Roessler S; Nahnsen S; Czemmel S; Dittrich-Breiholz O; Eggert T; Kühnel F; Wirth TC
Hepatology; 2021 Apr; 73(4):1399-1418. PubMed ID: 32716559
[TBL] [Abstract][Full Text] [Related]
17. IL15 Stimulation with TIGIT Blockade Reverses CD155-mediated NK-Cell Dysfunction in Melanoma.
Chauvin JM; Ka M; Pagliano O; Menna C; Ding Q; DeBlasio R; Sanders C; Hou J; Li XY; Ferrone S; Davar D; Kirkwood JM; Johnston RJ; Korman AJ; Smyth MJ; Zarour HM
Clin Cancer Res; 2020 Oct; 26(20):5520-5533. PubMed ID: 32591463
[TBL] [Abstract][Full Text] [Related]
18. T-cell immunoglobulin and ITIM domain (TIGIT) receptor/poliovirus receptor (PVR) ligand engagement suppresses interferon-γ production of natural killer cells via β-arrestin 2-mediated negative signaling.
Li M; Xia P; Du Y; Liu S; Huang G; Chen J; Zhang H; Hou N; Cheng X; Zhou L; Li P; Yang X; Fan Z
J Biol Chem; 2014 Jun; 289(25):17647-57. PubMed ID: 24817116
[TBL] [Abstract][Full Text] [Related]
19. Immune Exhaustion of T Cells in Alveolar Echinococcosis Patients and Its Reversal by Blocking Checkpoint Receptor TIGIT in a Murine Model.
Zhang C; Lin R; Li Z; Yang S; Bi X; Wang H; Aini A; Zhang N; Abulizi A; Sun C; Li L; Zhao Z; Qin R; Li X; Li L; Aji T; Shao Y; Vuitton DA; Tian Z; Wen H
Hepatology; 2020 Apr; 71(4):1297-1315. PubMed ID: 31410870
[TBL] [Abstract][Full Text] [Related]
20. TIGIT/CD155 axis mediates resistance to immunotherapy in patients with melanoma with the inflamed tumor microenvironment.
Kawashima S; Inozume T; Kawazu M; Ueno T; Nagasaki J; Tanji E; Honobe A; Ohnuma T; Kawamura T; Umeda Y; Nakamura Y; Kawasaki T; Kiniwa Y; Yamasaki O; Fukushima S; Ikehara Y; Mano H; Suzuki Y; Nishikawa H; Matsue H; Togashi Y
J Immunother Cancer; 2021 Nov; 9(11):. PubMed ID: 34795004
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]